Pharmacy & Therapeutics - March 2008 - (Page 175) CONTINUING EDUCATION CREDIT diabetic neuropathy pain in patients with normal or depressed mood. Neurology 1987;37:589–596. Argoff CE, Backonja MM, Belgrade MJ, et al. Consensus guidelines: Treatment planning and options. Mayo Clin Proc 2006;81(4 Suppl):S12–S25. Joss JD. Tricyclic antidepressant use in diabetic neuropathy. Ann Pharmacother 1999;33:996–1000. McQuay HJ, Tramer M, Carroll ND, et al. A systematic review of antidepressants in neuropathic pain. Pain 1996;68:217–227. Sindrup SH, Ejlertsen B, Froland A, et al. Imipramine treatment in diabetic neuropathy: Relief of subjective symptoms without changes in peripheral and autonomic nerve function. Eur J Clin Pharmacol 1989;37:151–153. Kvinesdal B, Molin J, Froland A, et al. Imipramine treatment of painful diabetic neuropathy. JAMA 1984;251:1727–1730. Turkington RW. Depression masquerading as diabetic neuropathy. JAMA 1980;243:1147–1150. Max MB, Kishore-Kumar R, Schafer SC, et al. Ef ficacy of desipramine in painful diabetic neuropathy: A placebo-controlled trial. Pain 1991;45:3–9. Max MB, L ynch SU, Muir J, et al. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992;326:1250–1256. Cymbalta (duloxetine), package insert. Indianapolis, IN: Eli Lilly; 2007. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine, 60 mg once daily, for major depressive disorder: A randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002;36:383–390. Nemeroff CB, Schatzberg AF, Goldstein DJ, et al. Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull 2002:36(4):106–132. Goldstein DJ, Mallinckrodt C, Lu Y, et al. Efficacy and safety of duloxetine 120 mg/day in the treatment of depression. J Affect Disord 2002;68:108. Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005;116:109–118. Raskin J, Pritchett YL, Wang F, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005; 6:346–356. Raskin J, Smith TR, Wong K, et al. Duloxetine versus routine care in the long term treatment of diabetic peripheral neuropathic pain. J Palliat Med 2006;9(1):29–40. Lacy C, Armstrong L, Goldman M, Lance L. Drug Information Handbook, 13th ed. Cleveland, OH: Lexicomp, Inc.; 2005. Rowbotham MC, Golil V, Kunz NR, et al. Venlafaxine extended release in the treatment of painful diabetic neuropathy: A doubleblind, placebo-controlled study. Pain 2004;(110):697–706. Sindrup SH, Bach BW, Madsen C, et al. Venlafaxine versus imipramine in painful polyneuropathy. Neurology 2003;60:1284– 1289. Gorson KC, Rand WM. Gabapentin in the treatment of painful diabetic neuropathy: A placebo-controlled, double-blind, crossover trial. J Neurol Neurosurg Psychiatry 1999;66:251–252. Backonja M, Beydoun A, Edwards K, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998; 280(21):1831–1836. Morello CM, Leckband SG, Stoner CP. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med 1999;159: 1931–1937. Dallocchio C, Buffa C, Mazzarello P, Chiroli S. Gabapentin vs. amitriptyline in painful diabetic neuropathy: An open-label pilot study. J Pain Symptom Manage 2000;20(4):280–285. Frampton JE, Scott LJ. Pregabalin in the treatment of painful diabetic peripheral neuropathy. Drugs 2004;64(24):2813–2820. Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: A randomized controlled trial. Neurology 2004;63:2104–2110. Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: A double-blind, placebo-controlled trial. Pain 2004;110(3):628–638. 31. Richter RW, Portenoy R, Sharma U, et al. Relief of painful diabetic peripheral neuropathy with pregabalin: A randomized, placebocontrolled trial. J Pain 2005;6(4):253–260. 32. Freynhagen R, Strojek K, Griesing T, et al. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, doubleblind, multicentre, placebo-controlled trial of flexible- and fixeddose regimens. Pain 2005;115:254–263. 33. Dogra S, Beydoun S, Mazzola J, et al. Oxcarbazepine in painful diabetic neuropathy: A randomized, placebo-controlled study. Eur J Pain 2005;9:543–554. 34. Beydoun A, Shaibani a, Hopwood M, Wan Y. Oxcarbazepine in painful diabetic neuropathy: Results of a dose-ranging study Acta Neurol Scand 2006;113:395–404. 35. Grosskopf J, Mazzola J, Wan Y, Hopwood M. A randomized, placebo-controlled study of oxcarbazepine in painful diabetic neuropathy. Acta Neurol Scand 2006;114:177–180. 36. Eisenberg E, Lurie Y, Braker C, et al. Lamotrigine reduces painful diabetic neurotherapy: A randomized, controlled study. Neurology 2001;57:505–509. 37. Vinik A, Tuchman M, Safirstein B, et al. Lamotrigine for treatment of pain associated with diabetic neuropathy: Results of two randomized, double-blind, placebo-controlled studies. Pain 2007; 128:169–179. 38. Jose V, Bhansali A, Hota D, Pandhi P. Randomized double-blind study comparing the efficacy and safety of lamotrigine and amitriptyline in painful diabetic neuropathy. Diabetic Med 2007;24: 377–383. 39. Lidoderm (Lidocaine), package insert. Chadds Ford, PA: Endo; 2006. 40. Meier T, Wasner G, Faust M, et al. Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: A randomized, double-blind, placebo-controlled study. Pain 2003;106(1–2):151–158. 41. Barbano RL, Hermann DN, Hari-Goulea S, et al. Effectiveness, tolerability and impact of quality of life of the 5% lidocaine patch in diabetic polyneuropathy. Arch Neurol 2004;61:914–918. 42. Argoff CE, Galer BS, Jensen MP, et al. Effectiveness of the lidocaine patch 5% on pain qualities in three chronic pain states: Assessment with the neuropathic pain scale. Curr Med Res Opin 2004;20(2):S21–S28. 43. Namaka M, Gramlich CR, Ruhlen D, et al. A treatment algorithm for neuropathic pain. Clin Ther 2004;26(7):951–979. 44. Donofrio P, Walker F, Hunt V, et al. (Capsaicin Study Group). Treatment of painful diabetic neuropathy with topical capsaicin. Arch Intern Med 1991;151:2225–2229. 45. Donofrio P, Walker F, Hunt V, et al. (Capsaicin Study Group). Effect of treatment with capsaicin on daily activities of patients with painful diabetic neuropathy. Diabetes Care 1992;15(2):159– 165. 46. Gimbel J, Richards P, Portenoy R. Controlled-release oxycodone for pain in diabetic neuropathy: A randomized controlled trial. Neurology 2003;60:927–934. 47. Watson C, Moulin D, Watt-Watson J, et al. Controlled-release oxycodone relieves neuropathic pain: A randomized controlled trial in painful diabetic neuropathy. Pain 2003;105:71–78. 48. Harati Y, Gooch C, Swenson M, et al. Maintenance of the longterm effectiveness of tramadol in treatment of the pain of diabetic neuropathy. J Diabetes Complications 2000;14:65–70. 49. Freeman R, Raskin P, Hewitt D, et al. Randomized study of tramadol/acetaminophen versus placebo in painful diabetic peripheral neuropathy. Curr Med Res Opin 2007;23(1):147–161. 50. Metanx. Available at: www.metanx.com/Healthcare Professionals,MedicalReferences. Accessed August 3, 2007. 51. Buysschaert M, Dramais AS, Wallemacq PD, et al. Hyperhomocysteinemia in type 2 diabetes: Relationship to macroangiopathy, nephropathy, and insulin resistance. Diabetes Care 2000;23(12): 1816–1822. 52. De Luis DA, Fernandez N, Arranz ML, et al. Total homocysteine levels: Relation with chronic complications of diabetes, body composition, and other cardiovascular risk factors in a population of 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. Vol. 33 No. 3 • March 2008 • P&T® 175 http://www.metanx.com/HealthcareProfessionals http://www.metanx.com/HealthcareProfessionals
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.